Amicus Therapeutics Inc/ US03152W1099 /
| 5/24/2024 10:00:00 PM | Chg. +0.1900 | Volume | Bid12:00:01 AM | Ask12:00:01 AM | High | Low |
|---|---|---|---|---|---|---|
| 9.6600USD | +2.01% | 3.17 mill. Turnover: 25.37 mill. |
9.0900Bid Size: 500 | 9.7500Ask Size: 3,800 | 9.6900 | 9.4200 |
GlobeNewswire
5/9
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
5/1
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
3/20
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
GlobeNewswire
2/28
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
GlobeNewswire
2/15
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire
2/8
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga)...
GlobeNewswire
2/1
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
GlobeNewswire
1/7
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
GlobeNewswire
1/3
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
12/5/2023
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next Presiden...
GlobeNewswire
11/8/2023
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
GlobeNewswire
11/1/2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
GlobeNewswire
10/27/2023
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
GlobeNewswire
10/3/2023
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
GlobeNewswire
10/2/2023
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
GlobeNewswire
9/28/2023
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda f...
GlobeNewswire
9/28/2023
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
GlobeNewswire
9/21/2023
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice Preside...
GlobeNewswire
9/14/2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
9/1/2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
GlobeNewswire
8/29/2023
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
